Evidence map›Paper›PMID 40341189›Full record

ArticleScientific reports2025

The cancer stem cells characteristics analysis of LGR5 + cells that influence lung cancer risk by using single cell RNA-seq analysis.

Ge Wen, Shaoqing Niu, Shiqi Mei, Senming Wang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ge WenDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Shaoqing NiuDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Shiqi MeiDepartment of Oncology, The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510280, China.
Senming WangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. wsm@smu.edu.cn.

Funding

grants from Natural Science Foundation of Guangdong Province, China 2023A1515011600
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most popular lung cancer type with highly mortality. We performed a single cell RNA-seq analysis to explore characteristic of cancer stem cells in LUAD. We downloaded the single cell RNA-seq data (GSE149655) from the GEO database, the scRNA-seq analysis was performed by using the "Seurat" and "harmony" R package. The FindMarkers function and "ClusterProlifer" package was used for differentially expressed genes (DEGs) and function enrichment analysis. The protein-protein interaction and transcriptional regulatory network were performed by STRING and ChIPBase database. Immunohistochemistry tests to be used to observe differences in the expression of specific genes in LUAD and paracancerous tissue samples. BEAS-2B and A549 cells was used for vitro assay and the qRT-PCR, western blotting, wound healing, trans-well assays, EdU tests, and flow cytometry were performed. A total of 9 cell clusters were obtained after scRNA-seq analysis, in which the cancer stem cells had higher proportion in LUAD samples. Subsequently, function enrichment analysis revealed that the amino sugar and nucleotide sugar metabolism and DNA replication pathways were activated in cancer stem cells (CSCs), which were further sub-divided into 3 subtypes, the LGR5 + stem cell is a major contributor to cancer progression, its hub genes, such as HLA-DPB1, CD74, CTSH and HLA-DRB5 mediated the unique transcriptional state. In addition, the marker genes of three CSCs were also overexpressed in LUAD cells and the CXCL3 played an important role in mediating cell proliferation, apoptosis, migration and invasion of tumor. We performed a scRNA-seq analysis and identified the LGR5 + stem cell as a major contributor in LUAD progression, our findings are expected to provide new insights into the pathogenesis of LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsNeoplastic Stem CellsReceptors, G-Protein-CoupledSingle-Cell AnalysisA549 CellsBiomarkers, TumorCell Line, TumorCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansRNA-SeqSequence Analysis, RNABiomarkers, TumorLGR5 protein, humanReceptors, G-Protein-CoupledDrug resistanceLGR5 + stem cellsLung adenocarcinomaSingle-cell RNA sequencingTumor heterogeneity

Identifiers

PMID40341189
PMCPMC12062498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.